Actinium Pharmaceuticals, Inc. (Delaware)

4.55 USD
+0.37 (+8.85%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Actinium Pharmaceuticals, Inc. (Delaware) stock is down -18.46% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 10 December’s closed higher than November.

About Actinium Pharmaceuticals, Inc. (Delaware)

Actinium Pharmaceuticals, Inc. focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning. The company also offers clinical and preclinical development programs that utilize multiple isotopes.